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Introduction {#sec1}
============

*BRCA1* and *CREB-Binding protein (CREBBP or CBP)* are tumor suppressor genes that are important in normal development. Homozygous germline mutations in either of these genes are embryonic lethal in humans and mice. In humans, heterozygous germline *CREBBP* mutations cause Rubenstein-Taybi Syndrome, a developmental disorder (short stature, intellectual disability, etc.) that includes a predisposition to leukemia ([@bib18], [@bib24]). Unlike *CREBBP* mutations, *BRCA1* mutations do not predispose humans to hematopoietic neoplasia but do predispose to other solid tumors, such as pancreatic and prostate cancers, in addition to breast and ovarian cancers ([@bib5], [@bib17]).

Mice haploinsufficient for *Crebbp* develop myeloproliferative disorders and myelodysplastic syndromes by 1 year of age, which can progress to full-blown malignancies ([@bib12], [@bib30], [@bib32]). Complete deletion of *Crebbp* in hematopoietic stem cells (HSCs) impairs T and B cell development ([@bib10], [@bib27]) and increases differentiation to granulocytic and monocytic lineages ([@bib4]). In addition, either mono- or biallelic loss of Crebbp in bone marrow is reported to impair the self-renewing capacity of HSCs ([@bib4], [@bib23]).

Although *BRCA1* mutations do not predispose mice to leukemia, mice conditionally deficient for *Brca1* in embryonic HSCs develop a severe pancytopenia and die within 3 months of age ([@bib16]). This is quite different from mice conditionally deficient for *Brca1* in adult HSCs and progenitors using Mx1-Cre activation, which leads to a modest reduction in HSCs and mild bone marrow dysfunction ([@bib26]).

Although *Crebbp* and *Brca1* are both required to preserve normal HSC pools in bone marrow, their individual deficiencies result in distinct consequences ([@bib4], [@bib12], [@bib16], [@bib26], [@bib32]). To investigate functional interactions of *Brca1* and *Crebbp* in hematopoiesis, we co-deleted both genes in HSCs and progenitors using the hematopoietic system-specific Vav1-iCre ([@bib6]). Unexpectedly, we found that *Crebbp*-deficiency phenotypes are dependent on the presence or absence of *Brca1*. *Crebbp* deficiency in the background of normal *Brca1* led to leukocytosis and neutrophilia, whereas co-deletion of *Crebbp* with *Brca1* led to a more severe pancytopenia than that found for *Brca1* deficiency alone. We also show that, in contrast to previous studies ([@bib4], [@bib31], [@bib32]), hematopoietic loss of *Crebbp* alone resulted in a shift in the balance of HSCs where the decrease in the bone marrow was made up for in an increase in the spleen, rather than an overall shortage of HSCs. Furthermore, *Crebbp* heterozygosity showed enhanced hematopoietic defects in young mice with *Brca1*-deleted bone marrow, whereas *Brca1* heterozygosity showed mild attenuation of pathogenic consequences in *Crebbp*-deficient mice. Further support for a functional interaction between BRCA1 and CREBBP was found where BRCA1 levels were altered in *Crebbp*-deficient thymus and bone marrow-derived macrophages (BMDMs), adding support that these two genes cooperate *in vivo*.

Results {#sec2}
=======

Deficiency of *Crebbp* in Mouse Hematopoietic Tissue Leads to an Inflammatory Disorder {#sec2.1}
--------------------------------------------------------------------------------------

We, and others, have discovered that deletion of *Brca1* in HSCs results in either hematopoietic failure by 1 month of age when deleted in embryonic HSCs or a moderate reduction in bone marrow function when deleted in adult HSCs ([@bib16], [@bib26]). *Crebbp* has also been shown to contribute to maintenance of normal levels of early progenitors ([@bib12]). Since *Brca1* and *Crebbp* are important in hematopoiesis, we tested the functional interaction of these genes in knockout mice. Specifically, we conditionally deleted *Crebbp* alone or with *Brca1* using the early hematopoietic system-specific Vav1-iCre ([@bib6]) and compared them with previously described Vav1-iCre;*Brca1*^F/F^ mice ([@bib16]).

Vav1-iCre;*Crebbp*^F/F^ mice survived a median 86 days ([Figure 1](#fig1){ref-type="fig"}A), and their mortality was associated with an unexpected severe skin phenotype ([Figure 1](#fig1){ref-type="fig"}B). This included skin flaking that began at 4--5 weeks of age with alopecia in the tail, eyelids, and ears. This progressed to widespread alopecia, flaking, and ulceration by 3--4 months of age. Once severe dermatitis developed, mice became moribund and were euthanized. Similar to age-matched controls ([Figure 1](#fig1){ref-type="fig"}C), skin from young pre-symptomatic Vav1-iCre;*Crebbp*^F/F^ mice showed normal epidermal structure ([Figure 1](#fig1){ref-type="fig"}D, left). However, higher magnification showed abnormal granulocyte infiltration (black arrows) in the dermal layers ([Figure 1](#fig1){ref-type="fig"}D, right). Compared with normal skin structure in adult mice ([Figure 1](#fig1){ref-type="fig"}E), diseased Vav1-iCre;*Crebbp*^F/F^ adult mice showed significant epidermal hyper-proliferation and a fibrotic dermal layer ([Figure 1](#fig1){ref-type="fig"}F, left) with granulocytes (black arrows) and mast cells (white arrow) ([Figure 1](#fig1){ref-type="fig"}F, right). Unlike biallelic *Crebbp*-deficient mice, heterozygous Vav1-iCre;*Crebbp*^F/+^ mice showed long-term survival and did not have skin abnormalities during their lifespan (data not shown).Figure 1Deficiency of *Crebbp* in Mouse Hematopoietic Tissue Leads to an Inflammatory Disorder(A and B) (A) Kaplan-Meier curves show that mice with hematopoietic deletion of *Crebbp* (Vav1-iCre;*Crebbp*^F/F^) experienced early lethality (LD50 = 86 days, n = 14) that was associated with a systemic inflammatory disorder that progressed to (B) severe ulcerative dermatitis by 3--4 months of age.(C--I) (C) Representative H&E stains of skin cross sections from young (∼6 weeks) (C) WT and (D) Vav1-iCre;*Crebbp*^F/F^ and adult (∼4 months) (E) WT and (F) diseased Vav1-iCre;*Crebbp*^F/F^ mice (left \[low magnification\] and right \[high magnification\] panels). (D) Young Vav1-iCre;*Crebbp*^F/F^ had dermal granulocyte infiltration (right panel, black arrow) with normal epidermis. (F) Adult *Crebbp*-deficient mice had epidermal hyper-proliferation and immune infiltration of the dermis including mast cells (right panel, white arrow) and granulocytes (right panel, black arrow). Compared with (G) young and (I) adult WT lungs, (H) young Vav1-iCre;*Crebbp*^F/F^ lungs had foamy macrophages (white arrow), granulocytes (black arrow), and plasma cell accumulation (hatched arrow).(J) Adult Vav1-iCre;*Crebbp*^F/F^ had frequent Russell bodies (orange arrow) within plasma cell accumulations (right panel, hatched arrow).Abbreviations: WT, wild-type; *Crebbp*^Δ/Δ^, Vav1-iCre;*Crebbp*^F/F^.

Young Vav1-iCre;*Crebbp*^F/F^ mice also showed lung inflammation ([Figure 1](#fig1){ref-type="fig"}H, left). Higher magnification ([Figure 1](#fig1){ref-type="fig"}H, right) showed localized plasma cell accumulations (hatched arrow) and pockets of foamy macrophages (white arrow) that accompanied granulocyte infiltration (black arrows). Immune cell infiltration persisted in lungs of older diseased Vav1-iCre;*Crebbp*^F/F^ mice ([Figure 1](#fig1){ref-type="fig"}J, left), with frequent Immunoglobulin-rich Russell bodies (orange arrows) in plasma cell-dense regions (hatched arrow) of the lungs ([Figure 1](#fig1){ref-type="fig"}J, right). Representative WT lungs from young ([Figure 1](#fig1){ref-type="fig"}G) and adult ([Figure 1](#fig1){ref-type="fig"}I) mice are shown for comparison.

Similar to other *Crebbp*-deficiency studies ([@bib12], [@bib30], [@bib32]), Vav1-iCre;*Crebbp*^F/F^ mice developed splenomegaly ([Figure 2](#fig2){ref-type="fig"}A). Compared with controls *Crebbp*-deficient spleens were enlarged as early as 1 month of age (1.2% of body weight versus 0.5% body weight in control, p \< 0.0001) ([Figure 2](#fig2){ref-type="fig"}A, left) and by adulthood ([Figure 2](#fig2){ref-type="fig"}A, right) had ∼6-fold greater spleen weight than littermate controls (2.7% of body weight in *Crebbp*-deficient mice compared with 0.5% in controls, p \< 0.01). In contrast to splenomegaly, bone marrow cellularity in Vav1-iCre;*Crebbp*^F/F^ mice was similar to controls ([Figure S1](#mmc1){ref-type="supplementary-material"}A).Figure 2Early Hematopoietic Deletion of *Crebbp* Leads to Leukocytosis(A--M) (A) Vav1-iCre;*Crebbp*^F/F^ mice (gray circles) had enlarged spleens (% body weight) compared with controls (open circles, Vav1-iCre negative) at 4--8 weeks (young, p \< 0.0001) and \>8--24 weeks (adult p \< 0.01). Representative H&E stains of spleens from (B) young and (C) adult control mice compared with (D) young and (E) adult Vav1-iCre;*Crebbp*^F/F^ mice had white pulp (WP) depletion and progressive extramedullary expansion in red pulp (RP) of *Crebbp*-deficient mice. Peripheral blood analyses of (F) white blood cells (WBC), (G) neutrophils (NE), (H) monocytes (MO), (I) eosinophils (EO), (J) lymphocytes (LY), (K) red blood cells (RBC), (L) hemoglobin (Hb), and (M) hematocrit (HCT) for young (4--8 weeks, n = 16) and adult (\>8--24 weeks, n = 22) mice with hematopoietic deletion of *Crebbp* (gray circles, Vav1-iCre;*Crebbp*^F/F^), compared with young (n = 68) and adult (n = 48) matched controls (open circles) showed a myeloid leukocytosis.(N--U) Flow cytometric analysis of bone marrow (left) and splenic (right) (N) HSCs, (O) CMPs, (P) GMPs, (Q) GMs, (R) B cell progenitors, (S) T cell progenitors, (T) MEPs, and (U) erythroid progenitors for 4- to 8-week-old *Crebbp*-deficient mice (Vav1-iCre;*Crebbp*^F/F^, n = 4--6) (filled gray circles), compared with age-matched littermate controls (clear circles, n = 15). [Spleen weight numbers]{.ul}: Vav1-iCre control: young n = 17, adult n = 7; Vav1-iCre:*Crebbp*^F/F^: young n = 7, adult n = 21.Values represent means ± SEM. Statistical significance was assessed using a two-tailed Student\'s t test (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001,\*\*\*\*p \< 0.0001).

Compared with age-matched controls ([Figures 2](#fig2){ref-type="fig"}B and 2C), H&E stains from young and adult Vav1-iCre;*Crebbp*^F/F^ mice ([Figures 2](#fig2){ref-type="fig"}D and 2E) showed age-related progression of extramedullary hematopoiesis in red pulp with concomitant depletion of lymphoid structure in white pulp.

In parallel with the inflammatory phenotype, Vav1-iCre;*Crebbp*^F/F^ mice had leukocytosis. Elevated white blood cells (WBCs) ([Figure 2](#fig2){ref-type="fig"}F) were present in young *Crebbp*-deficient mice (4--8 weeks) and persisted throughout adulthood (8--24 weeks) (gray circles). The WBC differential showed Vav1-iCre;*Crebbp*^F/F^ mice had neutrophilia, monocytosis, and eosinophilia, with neutrophils increasing with age ([Figures 2](#fig2){ref-type="fig"}G--2I). Lymphocyte counts were normal ([Figure 2](#fig2){ref-type="fig"}J). In contrast to the previous reports of Mx1-Cre-mediated deletion of *Crebbp* in adulthood ([@bib4]), we did not observe thrombocytopenia in Vav1-iCre;*Crebbp*^F/F^ mice ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Both young and adult *Crebbp*-deficient mice were anemic ([Figures 2](#fig2){ref-type="fig"}K--2M).

HSC frequencies (CD150^+^CD48^−^Lineage^-^Sca-1^+^ckit^+^;CD150^+^CD48^−^LSK) ([@bib11]) in bone marrow from 4- to 8-week-old Vav1-iCre;*Crebbp*^F/F^ mice were lower compared with age-matched littermate controls ([Figure 2](#fig2){ref-type="fig"}N, left). Although this finding is consistent with previous reports ([@bib4]), we also noted an increase in splenic HSCs ([Figure 2](#fig2){ref-type="fig"}N, right). Both spleen and bone marrow from 4 to 8 week-old *Crebbp*-deficient mice showed higher levels of common myeloid progenitors (CMP, CD34^+^CD16/32^low^ CD127^−^Sca-1^−^LK), myeloid granulocyte/monocyte mid progenitors (GMP; CD34^+^CD16/32^high^ CD127^−^Sca-1^−^LK) ([@bib2]), and granulocyte/monocyte late progenitors (Gr1^+^Mac1^+^; CD11b^+^Gr1^+^) ([Figures 2](#fig2){ref-type="fig"}O--2Q), as well as CD3^+^T cell progenitors ([Figure 2](#fig2){ref-type="fig"}S). In agreement with previous reports identifying a role for CREBBP in B cell maturation ([@bib27], [@bib31]), loss of *Crebbp* in bone marrow resulted in significantly reduced ProB/PreB-cell frequencies (CD43^-^B220^hi^/B220^lo^) in bone marrow ([Figure 2](#fig2){ref-type="fig"}R, left) with less of an effect in spleen ([Figure 2](#fig2){ref-type="fig"}R, right). The inverse changes in T and B cell progenitor frequencies in *Crebbp*-null mice may explain the lack of net changes in total lymphocyte counts ([Figure 2](#fig2){ref-type="fig"}J). Megakaryocyte/erythroid mid progenitors (MEPs; CD34^−^CD16/32^low^CD127^−^Sca-1^−^LK) ([@bib2]) were higher in Vav1-iCre;*Crebbp*^F/F^ bone marrow and spleen, but only splenic late erythroid progenitors were higher ([Figures 2](#fig2){ref-type="fig"}T and 2U).

This is the first report of the use of the *Vav-Cre* allele to achieve biallelic deletion of *Crebbp* in adult and embryonic HSCs. These robust phenotypic data (inflammatory disorder, myeloproliferation) complement prior reports of *Crebbp* deficiency phenotypes. The other reports either studied heterozygous germline *Crebbp* knockouts or used the Mx1-Cre allele to achieve biallelic deletion of *Crebbp* in HSCs. For comparison of previous results to the data presented here, we have included a table comparing phenotypes ([Table S1](#mmc1){ref-type="supplementary-material"}).

*Brca1* and *Crebbp* Co-deficiency in Hematopoietic Tissue Leads to Increased Mortality due to Severe Bone Marrow Failure {#sec2.2}
-------------------------------------------------------------------------------------------------------------------------

To investigate the functional interaction of *Brca1* and *Crebbp* genes in hematopoietic tissue, we deleted both genes in bone marrow and compared them with each of the single knockouts. To our surprise, Vav1-iCre;*Brca1*^F/F^;*Crebbp*^F/F^ (double *Crebbp/Brca1* knockout mice \[DKO\]) mice died much earlier (LD50 = 33 days) than Vav1-iCre;*Crebbp*^F/F^ (LD50 = 86 days) or our previously published Vav1-iCre;*Brca1*^F/F^ mice (LD50 = 88.5 days) ([Figure 3](#fig3){ref-type="fig"}A; p \< 0.001). The detrimental effect of *Brca1/Crebbp* co-deletion was also apparent in our ability to generate only eight DKO mice over 3 years, despite optimal breeding schemes. *Crebbp* loss in the DKO mice did not result in skin abnormalities, possibly because these mice did not survive to an age where severe skin phenotypes in Vav1-iCre;*Crebbp*^F/F^ mice developed (3--4 months of age). Histology of bone marrow from the DKO mice showed decreased cellularity ([Figures 3](#fig3){ref-type="fig"}B and 3C). Bone marrow cell numbers were 80% lower in DKOs compared with control mice ([Figure 3](#fig3){ref-type="fig"}D). As expected, DKOs showed absence of bone marrow HSCs ([Figure 3](#fig3){ref-type="fig"}E) and loss of most mid and late progenitors ([Figure S2](#mmc1){ref-type="supplementary-material"}). DKOs (open diamonds), like Vav1-iCre;*Brca1*^F/F^ (downward triangles), developed pancytopenia that was even a more severe than age-matched Vav1-iCre;*Brca1*^F/F^ mice ([Figures 3](#fig3){ref-type="fig"}F--3L). Together, these data show that *Crebbp* and *Brca1* have distinct effects on hematopoiesis, where *Crebbp* restrains aberrant leukocytosis and possible HSC mobilization and also compensates for *Brca1* loss to maintain HSCs/progenitors.Figure 3Double Knockout of *Brca1* and *Crebbp* in Hematopoietic Tissues Leads to Rapid Death Associated with Severe Bone Marrow Failure(A--C) (A) Kaplan-Meier survival analysis shows hematopoietic co-deletion of *Brca1* and *Crebbp* (Vav1-iCre *Brca1*^F/F^;*Crebbp*^F/F^, \[DKO\]) results in greater lethality (LD50 = 33 days, n = 6) than loss of either *Brca1* (Vav1-iCre;*Brca1*^F/F^, LD50 = 88.5 days, n = 8) or *Crebbp* (Vav1-iCre;*Crebbp*^F/F^, LD50 = 86, n = 12) alone, compared with littermate control mice (Vav1-iCre negative, n = 9). H&E stains show comparison of (B) normal bone marrow and (C) ablated bone marrow in DKO mice.(D--L) (D) Quantification of bone marrow counts in long bones (2x femur and tibia) show 80% decrease in cellularity in DKOs (WT, n = 15; DKO, n = 4). Early lethality in DKO mice correlates with (E) ablated HSCs (WT, n = 15; DKO, n = 4) and (F--L) more advanced pancytopenia compared with age-matched (4--8 weeks) mice with only *Brca1* deletion (Vav1-iCre;*Brca1*^F/F^). Peripheral (F) white blood cells (WBC), (G) neutrophils (NE), (H) monocytes (MO), (I) lymphocytes (LY), (J) red blood cells (RBC), (K) hemoglobin (Hb), and (L) platelets (PLT) are shown from 4- to 8-week-old mice. [Blood count numbers]{.ul}: Age-matched litter mate control (Vav1-iCre negative) n = 92 (open circles); Vav1-iCre;*Crebbp*^F/F^ n = 30 (gray circles); Vav1-iCre;*Brca1*^F/F^ n = 6 (open downward triangles); DKO n = 6, (open diamonds). Values represent means ± SEM. Statistical significance was assessed using a two-tailed Student\'s t test except in (A) where a long-rank test was used (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001).

*Brca1* and *Crebbp* Gene Dosage Impacts Hematopoiesis {#sec2.3}
------------------------------------------------------

Heterozygous *CREBBP* mutations in humans predispose patients with Rubenstein-Taybi Syndrome to hematopoietic neoplasia ([@bib18], [@bib24]). Also, *Brca1* heterozygosity has been associated with increased frequency of febrile neutropenia after chemotherapy ([@bib16]). Whether heterozygous mutations in either gene impact other phenotypes is not known. Here, we tested whether the heterozygous states of either *Crebbp* or *Brca1* affected the deficient phenotypes of the other. Combined *Brca1* and *Crebbp* heterozygosity (Vav1-iCre; *Brca1*^F/+^*;Crebbp*^F/+^) did not affect survival ([Figure 4](#fig4){ref-type="fig"}A, gray line) or CBCs ([Figures 4](#fig4){ref-type="fig"}B--4F, open circles versus open squares), except for a mild but significant increase in monocytes ([Figure 4](#fig4){ref-type="fig"}E). Mice with *Brca1* heterozygosity combined with complete *Crebbp* deficiency (Vav1-iCre; *Brca1*^F/+^*;Crebbp*^F/F^) showed slightly longer survival than Vav1-iCre;*Crebbp*^F/F^ mice, but this change was not significant (LD50 = 107 versus 86 days, p = 0.069) ([Figure 4](#fig4){ref-type="fig"}A, dotted versus solid line). However, young Vav1-iCre;*Brca1*^F/+^*;Crebbp*^F/F^ mice displayed lower WBC counts (p \< 0.05) compared with Vav1-iCre;*Crebbp*^F/F^ mice; individual counts for neutrophils (NE) (p = 0.073), monocytes (MO) (p = 0.06), and eosinophils (EO) (p = 0.094), although lower, were not significant ([Figures 4](#fig4){ref-type="fig"}B--4E; gray triangles versus gray circles). *Brca1* heterozygosity in Crebbp-deficient mice led to a decrease of RBC counts ([Figure 4](#fig4){ref-type="fig"}G, open circles versus gray triangles).Figure 4Heterozygosity of *Brca1* and *Crebbp* Has Hematopoietic Effects when There Is Complete Deficiency of the Other(A--Q) *Brca1* heterozygosity in *Crebbp*-deficient bone marrow (A) results in slight, but insignificant increase in survival (Kaplan Meier, p = 0.069), attenuates elevated peripheral (B) white blood cells (WBC), (C) neutrophils (NE), (D) eosinophils (EO), (E) monocytes (MO), and (G) red blood cells (RBC), but not (F) lymphocytes (LY), (H--O) normalizes splenic HSCs, attenuates elevated myeloid progenitors in bone marrow and spleen as well as late T cell progenitors in spleen, and (P) results in slight but insignificant decreased incidence of inflammatory skin disorder (filled versus clear bars). *Crebbp* heterozygosity (Q) does not alter Brca1-deficiency survival.(R--T) Progressive loss of *Crebbp* alleles in Brca1-deficient bone marrow results in intermediate decreases in WBCs, NE, and RBCs. [Survival curve numbers]{.ul}: Vav1-iCre; *Brca1*^F/+^;*Crebbp*^F/+^ n = 12, Vav1-iCre;*Crebbp*^F/F^ n = 14, Vav1-iCre; *Brca1*^F/+^;*Crebbp*^F/F^ n = 15, Vav1-iCre negative control n = 9, Vav1-iCre; *Brca1*^F/F^ n = 8, Vav1-iCre; *Brca1*^F/F^;*Crebbp*^F/+^ n = 20. [Blood count numbers]{.ul}: Vav1-iCre negative control (WT) n = 92, Vav1-iCre; *Brca1*^F/+^;*Crebbp*^F/+^ n = 26, Vav1-iCre;*Crebbp*^F/F^ n = 30, Vav1-iCre; *Brca1*^F/+^;*Crebbp*^F/F^ n = 20. [Progenitor mouse numbers]{.ul}: Vav1-iCre negative control n = 17, Vav1-iCre;*Crebbp*^F/F^ n = 5, Vav1-iCre; *Brca1*^F/+^;*Crebbp*^F/F^ n = 6. [Skin assessment numbers]{.ul}: Control mice (Vav1-iCre negative) n = 32, Vav1-iCre;*Crebbp*^F/F^ n = 18, Vav1-iCre; *Brca1*^F/+^;*Crebbp*^F/F^ n = 15.Values represent means ± SEM. Statistical significance was assessed using a two-tailed Student\'s t test except in (A) where a long-rank test was used and (P) where an Fisher\'s exact test was used (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001).

*Brca1* haploinsufficiency in Vav1-iCre; *Brca1*^F/+^*;Crebbp*^F/F^ mice (gray triangles) normalized splenic HSCs compared with *Crebbp*-deficient mice ([Figure 4](#fig4){ref-type="fig"}H, right; gray circles versus triangles) and attenuated most bone marrow myeloid progenitors. Except for late granulocyte/monocyte (Gr1^+^Mac1^+^) progenitors spleen showed similar trends ([Figures 4](#fig4){ref-type="fig"}I--4K). In addition, Vav1-iCre;*Brca1*^F/+^*; Crebbp*^F/F^ splenic T cells were normalized toward wild-type (WT) frequencies (open circles) ([Figure 4](#fig4){ref-type="fig"}L, right). *Brca1* heterozygosity (gray triangles) did not significantly alter *Crebbp*-deficiency-associated ProB/PreB loss in bone marrow ([Figure 4](#fig4){ref-type="fig"}M, left). Splenic early erythoid progenitors were unchanged ([Figure 4](#fig4){ref-type="fig"}N), whereas late erythroid progenitors were elevated in Vav1-iCre; *Brca1*^F/+^*;Crebbp*^F/F^ mice compared with controls ([Figure 4](#fig4){ref-type="fig"}O, right), although RBCs were decreased with *Brca1* heterozygosity ([Figure 4](#fig4){ref-type="fig"}G). We did observe a mild but insignificant reduction in lifetime incidence of skin abnormalities in Vav1-iCre; *Brca1*^F/+^*;Crebbp*^F/F^ compared with Vav1-iCre;*Crebbp*^F/F^ mice ([Figure 4](#fig4){ref-type="fig"}P; p = 0.083, Fisher\'s exact test).

Hematopoietic abnormalities have been previously reported for *Crebbp* heterozygous mice that appear in late adulthood (\>1 year) ([@bib12]). We tested whether a heterozygous *Crebbp* genetic background affected young mice that were *Brca1*-deficient. Although *Crebbp* heterozygosity did not alter lifespan of *Brca1*-deficient mice ([Figure 4](#fig4){ref-type="fig"}Q, Vav1-iCre;*Brca1*^F/F^;*Crebbp*^F/+^), WBC and neutrophil counts were moderately reduced ([Figures 4](#fig4){ref-type="fig"}R and 4S) and RBC counts trended lower ([Figure 4](#fig4){ref-type="fig"}T). That *Crebbp* and *Brca1* allele dosage influence the deficiency phenotype of the other is further evidence these two genes cooperate. However, it is not clear whether this cooperation is direct or indirect.

BRCA1 Protein Is Altered in CREBBP-Deficient Hematopoietic Tissues {#sec2.4}
------------------------------------------------------------------

Since previous data have shown that CREBBP regulates *BRCA1* gene expression ([@bib21], [@bib22]), we explored whether similar direct relationships were present in hematopoietic tissue. We chose thymus as our model hematopoietic tissue for two reasons: (1) thymus has robust mRNA signal for *Brca1* ([@bib7]) and (2) it is a less heterogeneous, T cell-restricted tissue compared with bone marrow and spleen.

Consistent with the prior report of transcriptional regulation of BRCA1 by CREBBP ([@bib21]), *Brca1* mRNA in the thymus of Vav-Cre;*Crebbp*^F/F^ mice ([Figure 5](#fig5){ref-type="fig"}A) was lower compared with WT BRCA1. Similarly, we found that Vav-Cre;*Crebbp*^F/F^ BRCA1 protein in thymus was decreased, but to a greater extent than mRNA ([Figures 5](#fig5){ref-type="fig"}C and 5D). The specific reactivity of the mouse BRCA1 antibody (Santa Cruz SC287.17) was established in WT thymus using fully humanized BRCA1 mouse thymus as a negative control ([Figure S3](#mmc1){ref-type="supplementary-material"}). Compared to WT, *Crebbp* deficiency in thymic tissue from Vav1-iCre;*Crebbp*^F/F^ mice was confirmed by loss of mRNA ([Figure 5](#fig5){ref-type="fig"}B) and protein ([Figure 5](#fig5){ref-type="fig"}E). To evaluate heterogeneity of cell types in the thymus, we performed flow cytometry on *Crebbp*-deficient thymic tissue. The data were consistent with prior reports ([@bib10], [@bib27]) where Vav1-iCre;*Crebbp*^F/F^ tissue showed a significant decrease in CD4+/CD8+ double-positive cell frequencies with a shift toward a higher frequency of CD4-/CD8- double-negative and CD8+ single-positive cells compared with WT ([Figure S4](#mmc1){ref-type="supplementary-material"}). Because *Brca1* expression may vary between CD4 and CD8 double-positive, single-positive, and double-negative T cells, it remains possible that differences in BRCA1 protein detected between WT and Vav1-iCre;*Crebbp*^F/F^ thymus arose from changes in T cell lineages with differing levels of BRCA1.Figure 5Decreased BRCA1 Protein Levels in CREBBP-Deficient Tissue(A--C) *Crebbp*-deficient thymus has decreased levels of (A) *Brca1* mRNA and (C) BRCA1 protein. *Crebbp*-deficiency in Vav1-iCre; *Crebbp*^F/F^ thymus was verified by (B) qPCR and (C) western blot.(D) and (E) show densitometry of western blot signal in thymus.(F--H) (F) BMDMs harvested after 6 days of culture in granulocyte-macrophage colony stimulating factor (GM-CSF) (20 ng/mL) from *Crebbp*-deficient bone marrow-derived macrophages (BMDMs) show similar *Brca1* mRNA in all genotypes but (H) lower BRCA1 protein. *Crebbp* deficiency in Vav1-iCre;*Crebbp*^F/F^ BMDMs was verified by (G) qPCR and (H) western blot.(I) and (J) show densitometric analysis of BMDM western blot data. Thymus *Brca1* mRNA was measured in WT (n = 10) and Vav1-iCre; *Crebbp*^F/F^(n = 5) mice. Thymic BRCA1 protein was measured in WT (n = 6) and Vav1-iCre; *Crebbp*^F/F^(n = 6) mice. BMDM *Brca1* mRNA was measured in WT (n = 5) and Vav1-iCre; *Crebbp*^F/F^(n = 5) mice. BMDM BRCA1 protein was measured in WT (n = 4) and Vav1-iCre;*Crebbp*^F/F^ mice (n = 5).Values represent means ± SEM. Statistical significance was assessed using a two-tailed Student\'s t test (\*\*\*p \< 0.001, \*\*\*\*p \< 0.0001).

To address issues of cell-type heterogeneity present in intact hematopoietic tissue, we also compared *Brca1* expression in primary bone marrow-derived macrophages (BMDMs) from WT and Vav1-iCre;*Crebbp*^F/F^ mice. qPCR showed that WT and Vav1-iCre;*Crebbp*^F/F^ differentiated BMDM cultures had similar expression levels of macrophage and dendritic cell markers F4/80 and CD11c, respectively, and suggests relative homogeneity between these two genotypes ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B, respectively). *Brca1* mRNA was not significantly different in the knockout and WT BMDMs ([Figure 5](#fig5){ref-type="fig"}F), whereas BRCA1 protein from *Crebbp*-deficient BMDMs was lower than in controls ([Figures 5](#fig5){ref-type="fig"}H and 5I). Compared to WT, *Crebbp* deficiency in BMDMs from Vav1-iCre;*Crebbp*^F/F^ mice was confirmed by loss of mRNA ([Figure 5](#fig5){ref-type="fig"}G) and protein ([Figure 5](#fig5){ref-type="fig"}J). To address whether reduced levels of BRCA1 in *Crebbp*-deficient BMDMs were indirectly associated with altered proliferation rates compared with WT, we performed propidium iodide stain cell cycle analysis and found both genotypes to have similar fraction of cells in G1, G2, and S phase ([Figure S5](#mmc1){ref-type="supplementary-material"}C). This is the first report of BRCA1 detection in macrophages and suggests that BRCA1 protein changes in *Crebbp*-deficient BMDMs are independent of proliferation rates and that CREBBP regulates BRCA1 using a post-transcriptional mechanism in BMDMs.

Discussion {#sec3}
==========

We show that mice deficient of *Crebbp* in the bone marrow present with a previously undescribed lethal systemic immune disorder that manifests as a fully penetrant, severe dermatitis and alopecia. This is consistent with a previous study that showed that a T-reg-specific double knockout of *Crebbp* and its paralog, p300, results in an early-onset lethal autoimmune disease that includes dermatitis ([@bib15]). In the latter study, absence of *Crebbp* alone in T-reg cells did not result in severe autoimmunity, which suggests that systemic inflammatory disease in the Vav1-iCre;*Crebbp*^F/F^ mice herein involves *Crebbp* deficiency in a broader set of immune cell types. It is clear from our studies, as well as earlier reports ([@bib10]), that *Crebbp* deficiency disrupts T cell homeostasis beyond T-reg function as shown with increase in CD8 single-positive cells in thymus. Whether this translates to elevation in CD8-positive autoreactive and effector T-cells to mediate full-blown skin disease needs further investigation. A role for neutrophils in autoimmune disease has been reported ([@bib20]). Therefore, presence of granulocytes in the dermal layers prior to skin abnormalities may potentiate later phases of autoimmune processes. Finally, it is also possible that *Crebbp-*deficient mice display impaired wound healing responses in the event that hematopoietic loss of *Crebbp* disrupts M2 macrophages differentiation or function.

*Crebbp* deficiency also led to a much earlier and more severe myeloproliferative phenotype compared with previous reports in older haploinsufficient mice ([@bib12], [@bib23], [@bib30], [@bib32]). This further confirms the importance of *Crebbp* in hematopoiesis and supports earlier studies that show that *Crebbp* acts as a key immune modulator of inflammatory cell activity and differentiation in the bone marrow ([@bib4], [@bib13], [@bib14], [@bib15]). Our data suggest that loss of *Crebbp* results in HSC mobilization, evidenced by HSC population balance shifting from bone marrow to spleen, as well as a consistent granulocytosis. The neutrophilia and monocytosis was a fully penetrant phenotype present before full-blown skin disease, suggesting that leukocytosis in *Crebbp*-deficient mice is an inherent, rather than acquired (e.g., infection), condition. Therefore, it is attractive to speculate that *Crebbp* is required to prevent inappropriate HSC mobilization and that modulating *Crebbp* may be a mechanism to regulate hematopoiesis and innate immune responses.

The abundance of splenic HSCs in our *Crebbp*-deficient mice show that *Crebbp* is not required to maintain an adequate pool of HSCs per se. This differs from previous reports that *Crebbp* displays cell autonomous and non-autonomous haploinsufficiency in bone marrow to maintain functional self-renewing HSCs ([@bib23], [@bib31]). These conclusions were based on reduced secondary transplant efficiency associated with lower LSK CD34-populations in the bone marrow of *Crebbp* heterozygous mice. Similarly, a later study showed that deletion of *Crebbp* in adult HSC also resulted in a lower reconstitution capacity as well as decreased frequency of LSK CD34^-^Flt3^-^ cells that was independent of mobilization to the spleen ([@bib4]). A possible reason for the discrepancy between our and earlier splenic HSC quantification is that we confine our estimation to the LSK CD150^+^CD48^-^ ([@bib11]) population that is more enriched for self-renewing HSCs, rather than multipotent and early progenitors, used in earlier studies. Owing to the mixed background of our mice in this study, we were unable to address the transplant repopulation capacity of *Crebbp*-deficient HSCs.

We show that co-deletion of tumor suppressors *Crebbp* and *Brca1* in bone marrow results in shortened lifespan compared with the already reduced survival of single knockouts. The advanced pancytopenia in DKOs highlights an ability of *Crebbp* to compensate for *Brca1* at an early stage of hematopoiesis. BRCA1 deficiency in cells is often associated with DNA damage-induced apoptosis that arises from defects in multiple pathways of DNA repair, including nuclear excision repair ([@bib8]), transcription-coupled repair of oxidative DNA damage ([@bib1]), homologous recombinational repair ([@bib19], [@bib25]), and non-homologous end-joining ([@bib3], [@bib28], [@bib29]). Since *Crebbp* has recently been shown to maintain genomic integrity during lineage specification of hematopoietic cells ([@bib9]), CREBBP may partially compensate for defective DNA repair in *Brca1*-deficient HSCs and progenitors. We hypothesize that combined deletion of *Brca1* and *Crebbp* results in more severe global DNA damage than with *Brca1* and *Crebbp* single knockouts and that accelerated accumulation of genomic abnormalities leads to accelerated cell death rather than transformation. We therefore hypothesize that complete inhibition or loss of both tumor suppressors in blood cancers may be synthetic lethal, and if it is, this concept could be exploited to develop therapeutic targets of each in either *Brca1*- or *Crebbp*-deficient cancers.

Finally, we show that BRCA1 protein is altered in *Crebbp*-deficient hematopoietic tissue. In thymus, decreased BRCA1 protein in *Crebbp*-deficient thymus correlates with decreased *Brca1* mRNA, which is consistent with prior reports that *Brca1* is under transcriptional regulation by *Crebbp* ([@bib21]). In contrast, *Crebbp*-deficient BMDMs have decreased BRCA1 protein with no significant decrease in *Brca1* mRNA, suggesting the possibility of post-transcriptional regulation of BRCA1 protein by CREBBP. Although our data show that BRCA1 levels are decreased in CREBBP-deficient hematopoietic tissue, our *in vivo* data do not support a simplistic hypothesis that *Crebbp*-deficient phenotypes arise owing to loss of BRCA1 protein. It is interesting to speculate that reduced leukocytosis with *Brca1* heterozygosity in *Crebbp*-deficient mice ([Figures 4](#fig4){ref-type="fig"}B--4D) may reflect a reduction of BRCA1 protein below haploinsufficient levels that occurs in WT mice.

The compensatory roles for *Brca1* and *Crebbp* will lead us to further investigate how these tumor suppressor genes cooperate in developmental systems and how heterozygosity of pathogenic mutations in each gene contributes to tumorigenesis that results from the loss of the other.

Limitations of the Study {#sec3.1}
------------------------

Key limitations of this study relate to the poor health of *Crebbp/Brca1* DKO mice. The number of surviving DKO mice was low, and this limited statistical power for more in depth *in vivo* analyses. For example, since hematopoietic tissue was depleted we could not expand primary cells in culture or perform extensive biochemical analyses. Inducible systems will circumvent early lethality and allow for the comparison of the acute effects of co-deleting both genes *in vivo* as well as in culture. Another significant limitation was our inability to assess HSC self-renewal capacities with transplantation experiments as the Crebbp allele was obtained from a mixed background.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Supplemental Information {#appsec2}
========================

Document S1. Transparent Methods, Figures S1--S5, and Table S1

We thank members of the Ross lab for their intellectual contributions to this work. This work was supported by NIH R01 HL132251-02, the Nancy Tartaglino Richards Cancer Genetics Research Fund, the Lucy and Henry Billingsley Fund and a Burroughs Wellcome Fund Clinical Scientist Award in Translational Research (TSR). TSR holds the Jeanne Ann Plitt Professorship in Breast Cancer Research and the H. Ben and Isabelle T. Decherd Chair in Internal Medicine at UT Southwestern Medical Center.

Author Contributions {#sec5}
====================

T.S.R., S.R.H., R.W., and V.E.M. conceived the study and designed/interpreted the experiments. S.R.H. and T.S.R. wrote the manuscript. S.R.H., R.W., K.M., and V.E.M. performed experiments and collected the data.

Declaration of Interests {#sec6}
========================

The authors declare no competing interests.

Supplemental Information can be found online at <https://doi.org/10.1016/j.isci.2019.08.031>.

[^1]: These authors contributed equally

[^2]: Lead Contact
